drugset / Trial / NCT03638206
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Phase 1/2
Unknown
73 enrolled
Shenzhen BinDeBio Ltd.
The First Affiliated Hospital of Zhengzhou University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cell immunotherapy | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |